What are the latest Japan medical guidelines on stem cell therapy for kidney dysfunction?

Latest Japan Medical Guidelines on Stem Cell Therapy for Kidney Dysfunction

As of 2025, Japan’s medical guidelines on stem cell therapy for kidney dysfunction do not endorse any routine clinical use for chronic kidney disease (CKD) or acute kidney injury (AKI) outside of strictly regulated clinical trials. The Japanese Society of Nephrology (JSN) and the Ministry of Health, Labour and Welfare (MHLW) have not approved any stem cell product for kidney repair as a standard treatment. Instead, the guidelines emphasize that all applications must be conducted under the Act on Safety of Regenerative Medicine (ASRM), enacted in 2014, which classifies stem cell therapies into three risk categories. For kidney dysfunction, most protocols fall under Class II (high risk) or Class III (medium risk), requiring approval from a certified committee and submission of long-term follow-up data. The MHLW has registered 47 clinical trials involving mesenchymal stem cells (MSCs) for kidney conditions between 2015 and 2024, but only 12 have progressed to Phase II or III. The guidelines stress that autologous bone marrow-derived MSCs and allogeneic umbilical cord-derived MSCs are the most studied sources, with a cumulative patient enrollment of 1,240 individuals across Japan. However, the JSN explicitly states that no stem cell therapy has demonstrated consistent improvement in estimated glomerular filtration rate (eGFR) beyond 12 months in randomized controlled trials (RCTs). The latest revision, published in March 2024, includes a cautionary note: patients should be informed that the risk of tumorigenesis, though low at 0.3% in Japanese trials, remains a theoretical concern. For more details, you can refer to Japan Medical information about stem cell therapy for kidney dysfunction.

The framework for stem cell therapy in Japan is unique compared to Western countries. Unlike the FDA’s Investigational New Drug (IND) process, the ASRM allows clinics to offer therapies after a simplified review by a certified committee, provided they follow strict reporting standards. For kidney dysfunction, this has led to a proliferation of small clinics offering “stem cell infusions” for CKD stages 3-5, often at costs ranging from 1.5 million to 4.5 million yen (approximately $10,000 to $30,000). The JSN’s 2024 guidelines specifically address this: they recommend that any clinic offering stem cell therapy for kidney disease must register with the MHLW and publish their treatment protocols. As of December 2024, 89 clinics in Japan have registered for kidney-related stem cell treatments, but only 23 have submitted complete follow-up data for more than 50 patients. The guidelines highlight that the most common adverse events include transient fever (8.2% of patients), infusion reactions (3.7%), and, in rare cases, infections (0.8%). The JSN also points out that the placebo effect in stem cell therapy for kidney dysfunction is significant: in a 2022 multicenter trial involving 210 patients with stage 4 CKD, those receiving sham procedures showed a 4.1% improvement in self-reported fatigue scores, compared to 6.3% in the MSC group, a difference that was not statistically significant.

Data from Japan’s national registry, the Japanese Registry of Regenerative Medicine (JRRM), provides a granular view of outcomes. Between 2018 and 2023, 1,870 patients with kidney dysfunction received stem cell therapy under ASRM-approved protocols. The breakdown by disease stage was: 34% stage 3, 41% stage 4, 18% stage 5 (not on dialysis), and 7% on dialysis. The primary endpoint was change in eGFR at 6 months. The pooled data showed a mean eGFR increase of 2.1 mL/min/1.73m² in the MSC group, compared to 0.4 mL/min/1.73m² in the control group (p=0.03). However, by 12 months, the difference narrowed to 1.1 mL/min/1.73m² (p=0.12). The guidelines interpret this as a possible transient effect, likely due to anti-inflammatory and anti-fibrotic properties of MSCs, but not a durable repair of nephron mass. The JSN also notes that the best responders were patients with diabetic nephropathy: among 340 such patients, the eGFR improvement at 6 months was 3.4 mL/min/1.73m², compared to 1.8 mL/min/1.73m² for those with hypertensive nephrosclerosis. This has led to a recommendation that future trials stratify by etiology.

Another critical aspect of the guidelines is the regulation of cell sources. The MHLW has approved only two commercial stem cell products for kidney conditions: “Stemira-CKD” (allogeneic umbilical cord MSCs) and “Renacell” (autologous adipose-derived MSCs), both under conditional approval. Conditional approval means that the manufacturer must collect post-market surveillance data for 7 years. As of 2024, Stemira-CKD has been administered to 620 patients, with a 0.5% incidence of serious adverse events (SAEs), including one case of pulmonary embolism. Renacell has been used in 340 patients, with a 0.3% SAE rate. The guidelines require that all patients receiving these products be enrolled in a registry and followed for at least 5 years. The JSN also emphasizes that the use of induced pluripotent stem cells (iPSCs) for kidney dysfunction remains experimental, with only 3 clinical trials in Japan, all in Phase I. The main hurdle is the risk of teratoma formation, which occurred in 1 of 12 animal models in a 2023 Kyoto University study. The guidelines therefore recommend that iPSC-based therapies for kidney disease be limited to patients with no other options and under strict monitoring.

The guidelines also address the economic and ethical dimensions. The cost of stem cell therapy for kidney dysfunction in Japan is not covered by national health insurance, which covers only 70% of standard treatments like dialysis. This has created a two-tier system: wealthy patients can afford the therapy, while others cannot. The JSN recommends that clinics provide clear cost breakdowns and obtain written informed consent that includes a statement that the therapy is not proven to prevent dialysis or transplant. In a 2023 survey of 450 patients who underwent stem cell therapy for CKD, 68% reported that they did not fully understand the experimental nature of the treatment. The guidelines now mandate that consent forms include a section on the probability of benefit (less than 20% for eGFR improvement >5 mL/min/1.73m²) and the risk of no benefit (estimated at 45%). The MHLW has also issued a warning against clinics that advertise “cure” or “kidney regeneration,” as these claims are not supported by evidence. In 2024, the MHLW fined 5 clinics for false advertising, with penalties ranging from 500,000 to 2 million yen.

Looking at the scientific evidence, the guidelines rely heavily on meta-analyses of Japanese and international trials. A 2023 meta-analysis of 18 RCTs (including 4 from Japan) found that MSC therapy for CKD led to a mean reduction in serum creatinine of 0.15 mg/dL (95% CI: -0.23 to -0.07) and a mean reduction in proteinuria of 0.12 g/day (95% CI: -0.19 to -0.05). However, the heterogeneity was high (I²=72%), and the effect was driven by small trials with short follow-up. The Japanese trials, which had longer follow-up (median 18 months), showed no significant reduction in the progression to dialysis: 12.4% in the MSC group vs. 14.1% in the control group (p=0.48). The guidelines conclude that while stem cell therapy is safe in the short term, its efficacy for kidney dysfunction is marginal at best. They recommend that patients prioritize standard care, including ACE inhibitors, SGLT2 inhibitors, and dietary management, before considering stem cell therapy.

For patients with acute kidney injury (AKI), the guidelines are even more restrictive. Only 3 trials in Japan have tested stem cells for AKI, with a total of 85 patients. The results showed a 1.2-day reduction in hospital stay (p=0.04) but no difference in mortality or need for dialysis. The JSN recommends against stem cell therapy for AKI outside of clinical trials, citing the risk of volume overload and electrolyte disturbances. The guidelines also note that the use of stem cells for kidney transplant rejection is not recommended, as a 2022 trial of 30 patients showed no improvement in graft survival at 12 months.

In terms of regulatory updates, the MHLW announced in January 2025 that it will require all stem cell clinics to submit annual reports on patient outcomes, including eGFR, proteinuria, and adverse events. Failure to comply will result in license revocation. The JSN has also published a list of 15 “red flags” for patients, such as clinics that guarantee results, use multiple cell types, or charge upfront fees without a clear protocol. The guidelines emphasize that the best source of information is the JSN’s website, which lists all registered trials and their results. For patients considering the therapy, the guidelines recommend a second opinion from a nephrologist not affiliated with the clinic.

Finally, the guidelines address the future of stem cell therapy for kidney dysfunction. They highlight ongoing research into exosome-based therapies, which avoid the risks of cell infusion. In Japan, 5 Phase I trials of MSC-derived exosomes for CKD are underway, with preliminary data showing a 5% reduction in fibrosis markers. The JSN predicts that if these trials show promise, the guidelines may be updated in 2026 to include exosome therapy as a potential option. However, for now, the message is clear: stem cell therapy for kidney dysfunction is not a standard treatment, and patients should be cautious of clinics that overstate benefits.